Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0038362 (stomatitis)
 8,852 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The RNA-dependent RNA polymerase associated with vesicular stomatitis virus has been found to be markedly inhibited at high concentrations of virus. This endogenous inhibitor of the virion transcriptase was completely reversed by the action of two negatively charged polyamino acids: poly(L-glutamic acid) and pepsin (EC 3.4.23.1). Two other polyanions, heparin and polyethylene sulfonate, strongly inhibited the activity of the virion transcriptase even at low virus concentrations. Poly (L-glutamic acid) rapidly released the block in transcription of concentrated vesicular stomatitis virus, possibly owing to competition for binding sites of the inhibitor on the virion nucleocapsid transcription complex.
 ...
PMID:Reversal by certain polyanions of an endogenous inhibitor of the vesicular stomatitis virus-associated transcriptase. 20 38

The effect of pepsin treatment at pH 4 on the infectivity of several enveloped viruses was assessed under the conditions used during the production of intravenous immunoglobulins. It was shown that the prototypes of four virus families--human immunodeficiency virus (Lentivirinae), herpes simplex virus type 1 and human cytomegalovirus (Herpesviridae), Semliki Forest virus (Togaviridae), and vesicular stomatitis virus (Rhabdoviridae)--were inactivated by this procedure. With vesicular stomatitis virus as a model, the contributions of both low pH and pepsin were demonstrated, and pepsin had a synergistic or additive action.
 ...
PMID:Virus inactivation during production of intravenous immunoglobulin. 164 3

Vilcek, Jan (New York University School of Medicine, New York, N.Y.), and John H. Freer. Inhibition of Sindbis virus plaque formation by extracts of Escherichia coli. J. Bacteriol. 92:1716-1722. 1966.-Extracts prepared from washed cells of Escherichia coli B by sonic treatment and subsequent filtration through a 0.45-mu membrane filter significantly inhibited plaque formation with Sindbis virus in cultures or primary chick embryo cells up to a dilution of 1:20,000. The inhibitor acted on the cells rather than directly on the virus. The inhibiting substance was nondialyzable. Treatment of crude extracts with nucleases, trypsin, chymotrypsin, pepsin, or ether had no effect on the activity. Treatment with pronase destroyed the virus-inhibiting effect. Extracts prepared from two strains of E. coli B and one strain of E. coli K-12 all showed inhibitory activity against Sindbis virus. The inhibitor was present in the cytoplasmic fraction of bacteria. It was also active against Sindbis virus in human cells and showed some activity against vesicular stomatitis and vaccinia viruses in different types of cells. Interferon was not shown to be involved in the inhibition, although actinomycin D partially reversed the inhibitory activity of the extracts.
 ...
PMID:Inhibition of Sindbis virus plaque formation by extracts of Escherichia coli. 428 59

Antivenoms are manufactured by the fractionation of animal plasma which may possibly be contaminated by infectious agents pathogenic to humans. This study was carried out to determine whether pre-existing antivenom production steps, as carried out by EgyVac in Egypt, may reduce viral risks. Two typical manufacturing steps were studied by performing down-scaled viral inactivation experiments: (a) a pH 3.3 pepsin digestion of diluted plasma at 30 degrees C for 1h, and (b) a caprylic acid treatment of a purified F(ab')2 fragment fraction at 18 degrees C for 1h. Three lipid-enveloped (LE) viruses [bovine viral diarrhoea virus (BVDV), pseudorabies virus (PRV), and vesicular stomatitis virus (VSV)] and one non-lipid-enveloped (NLE) virus [encephalomyocarditis virus (EMC)] were used as models. Kinetics of inactivation was determined by taking samples at 3 time-points during the treatments. The pH 3.3 pepsin digestion resulted in complete clearance of PRV (>7.0 log(10)) and in almost complete reduction of VSV (>4.5 but < or =6.4 log(10)), and in a limited inactivation of BVDV (1.7 log(10)). EMC inactivation was > or =2.5 but < or =5.7 log(10). The caprylic acid treatment resulted in complete inactivation of the 3 LE viruses tested: BVDV (>6.6 log(10)), PRV (>6.6 log(10)), and VSV (>7.0 log(10)). For EMC no significant reduction was obtained (0.7 log(10)). Cumulative reduction was >13.6, >11.5, >8.3 and > or =2.5 for PRV, VSV, BVDV and EMC, respectively. Therefore the current manufacturing processes of at least some animal antisera already include production steps that can ensure robust viral inactivation of LE viruses and moderate inactivation of a NLE virus.
 ...
PMID:Assessment of viral inactivation during pH 3.3 pepsin digestion and caprylic acid treatment of antivenoms. 1736 71